Praxis Precision Medicines (PRAX)

• Market cap: $4.71B
• 1 day: 2.33%
• 5 days: -1.29%
• 1 month: 1.4%
• 3 months: 293.61%
• 6 months: 422.27%
• Year to date: 137.1%
• 1 year: 136.68%
• 5 years: -69.24%
• 10 years: -54.79%
• Sector: Healthcare
• Industry: Biotechnology

About: Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Employees: 82